Pacific Stock Transfer Co. 4045 South Spencer St., Suite 403 Las Vegas, NV, 89119 702-361-3033 http://www.pacificstocktransfer.com info@pacificstocktransfer.com
* C-Virin – is a convenient, once-a-day oral formulation of ribavirin USP .Hepatitus C treatment
* C-Pegferon –is our brand of long-lasting, pegylated-interferon-alpha-2b. This product and C-Virin will be used together for the treatment of genotype 1, 2, 3, and 4 strains of hepatitis C virus.
* C-Vaxin – is a bivalent VLP vaccine and adjuvant combination designed to be used for the prevention of genotype-1 HCV infections or as an active-specific immunotherapy of chronic HCV disease .Hepatitus C treatment
* C-Immune – is a genotype-1-specific human immune globulin (antibody) product made by donor plasma fractionation, used for passive immunotherapy of HCV patients who fail to respond to ribavirin and interferon, and will be developed for the prevention or delay of graft re-infection by HCV in liver transplant recipients whose livers have failed due to chronic HCV infection.
Key Points From Recent News:
-Obtaining a third party valuation of $122 million for the Company as a component of an overall corporate financing.
-The securing of a worldwide, exclusive license for a platform vaccine technology from the National Institutes of Health which has applications initially for Hepatitis C ; but also has use in other applications such as cancer, nervous system disorders and obesity. The licensed platform technology has had approximately $10 million invested in it prior to the Company securing the license.
-Negotiating final terms with a formulation specialty company to make a C- Virin product line. Mr. Likes went on to say "the Company is aware of the continued downward pressure on the share price. However while the capitalization number does not currently reflect our value; with the third party valuation number currently being at $122 million and with there being approximately just under 20 million shares being issued, plus the other technologies which can be developed from our technology license, we believe we will demonstrate during the near, mid and long term execution of our business plan, that we bring value to our shareholders. We believe the market will reward us accordingly".